We are excited to share an update about the goals and design for the upcoming EXPLORE44™ study, a Phase 1/2 clinical trial evaluating AOC 1044 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44). AOC 1044 is an antibody oligonucleotide conjugate (AOC™) and is designed to use an antibody to deliver an exon 44-skipping oligonucleotide to muscle and heart cells. AOC 1044 is the first of multiple AOCs we are developing for the Duchenne community.

The goals of the EXPLORE44 study are to evaluate the safety and tolerability of AOC 1044 in healthy volunteers and participants with DMD44. EXPLORE44 will also look at the effects of AOC 1044 on dystrophin production, muscle strength and function, as well as other patient-reported outcomes and quality of life measures in participants with DMD44. The EXPLORE44 study will have two parts, Part A and Part B.

- Part A is expected to enroll 40 healthy volunteers and is planned to evaluate single ascending doses of AOC 1044 compared to placebo.
- Part B is planned to enroll 24 participants with DMD44 between the ages of 7 to 27 years old, including ambulatory and non-ambulatory participants. Part B is planned to evaluate multiple ascending doses of AOC 1044 compared to placebo.

The two-part design of EXPLORE44 enables the efficient safety and tolerability testing in healthy volunteers, while decreasing participation burden on participants living with DMD by not having them enroll in dose levels that we anticipate to be below the therapeutic range. At this time, we are initiating the healthy volunteer portion of the EXPLORE44 trial. We plan to give an update next year on when we anticipate initiating Part B in participants with DMD44.

All participants in EXPLORE44 will be randomly assigned to receive either AOC 1044 or a placebo (looks like AOC 1044 but contains no active drug) via intravenous, or IV, infusion, and they will also need to undergo muscle biopsies. All Part B participants have the option to enroll in an extension study after the completion of EXPLORE44, where everyone will receive active drug.

While the Phase 1 portion is running healthy volunteers, we are in the process of finalizing site selection and initiation activities with global clinical trial sites for participants with DMD44. We will continue to partner closely with the Duchenne advocacy community to provide you with more information and resources about EXPLORE44 as soon as they are available.

At Avidity, our clinical trial programs are designed in partnership with patients and their families, advocates, and leading physicians. EXPLORE44 has been designed in partnership with the patient community so that we can best meet the needs and
expectations of participants in our trials, as well as minimize barriers to participation. EXPLORE44 is planned to have support services in place to help offset the costs and challenges of participating in a clinical trial, including travel costs.

We share the sense of urgency with the Duchenne community and are excited about the potential to bring meaningful treatments to patients and families. We are grateful for your ongoing support and look forward to sharing more about EXPLORE44 with you soon.

Sincerely,
The Avidity Team